331: Postoperative Pain Relief Following Daycase Arthroscopic Shoulder Surgery

2008 ◽  
Vol 33 (5) ◽  
pp. e167-e167
Author(s):  
M BYRNE ◽  
C PINNOCK
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Shoulder Surgery ◽  
Postoperative Pain Relief ◽  
Arthroscopic Shoulder Surgery

Suprascapular Nerve Block for Postoperative Pain Relief in Arthroscopic Shoulder Surgery

1997 ◽  
Vol 84 (6) ◽  
pp. 1306-1312 ◽  
Author(s):  
Ewan D. Ritchie ◽  
Doris Tong ◽  
Frances Chung ◽  
Andrew M. Norris ◽  
Anthony Miniaci ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Nerve Block ◽  
Suprascapular Nerve ◽  
Shoulder Surgery ◽  
Postoperative Pain Relief ◽  
Suprascapular Nerve Block ◽  
Arthroscopic Shoulder Surgery

Suprascapular Nerve Block for Postoperative Pain Relief in Arthroscopic Shoulder Surgery

1997 ◽  
Vol 84 (6) ◽  
pp. 1306-1312 ◽  
Author(s):  
Ewan D. Ritchie ◽  
Doris Tong ◽  
Frances Chung ◽  
Andrew M. Norris ◽  
Anthony Miniaci ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Nerve Block ◽  
Suprascapular Nerve ◽  
Shoulder Surgery ◽  
Postoperative Pain Relief ◽  
Suprascapular Nerve Block ◽  
Arthroscopic Shoulder Surgery

Suprascapular Nerve Block for Postoperative Pain Relief in Arthroscopic Shoulder Surgery: A New Modality?

1998 ◽  
Vol 42 (3) ◽  
pp. 124
Author(s):  
EWAN D. RITCHIE ◽  
DORIS TONG ◽  
FRANCES CHUNG ◽  
ANDREW M. NORRIS ◽  
ANTHONY MINIACI ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Nerve Block ◽  
Suprascapular Nerve ◽  
Shoulder Surgery ◽  
Postoperative Pain Relief ◽  
Suprascapular Nerve Block ◽  
Arthroscopic Shoulder Surgery

Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: A randomized, phase IIIb study

2013 ◽  
Vol 9 (4) ◽  
pp. 281-290 ◽  
Author(s):  
Gary J. Vorsanger, PhD, MD ◽  
Angela M. Klopfer, BS ◽  
Jim Xiang, PhD ◽  
Carmela J. Benson, MS ◽  
Bruce L. Moskovitz, MD ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Pain Intensity ◽  
Immediate Release ◽  
Similar Efficacy ◽  
Shoulder Surgery ◽  
Included Patient ◽  
Phase Iiib ◽  
Arthroscopic Shoulder Surgery ◽  
Global Impression Of Change

Objective: Arthroscopic shoulder surgery can result in substantial postoperative pain. This study evaluated the efficacy and safety of tapentadol immediate release (IR) or oxycodone IR in this setting for the treatment of acute pain.Design: Subjects received tapentadol IR 50 or 100 mg or oxycodone IR 5 or 10 mg every 4-6 hours as needed for pain up to 7 days after arthroscopic shoulder surgery. Twice daily, subjects recorded pain intensity from 0 (no pain) to 10 (pain as bad as you can imagine) and pain relief from 0 (none) to 5 (complete). Final assessments included patient and clinician global impression of change and subject satisfaction with treatment. The primary efficacy endpoint was the sum of pain intensity differences (SPID) over 3 days.Results: Of 378 subjects (192 tapentadol IR, 186 oxycodone IR) who took study medication, 312 (158 tapentadol IR, 154 oxycodone IR) had pain intensity ≥4 before the first dose and were evaluated for efficacy. Mean SPID scores over 3 days were 32.1 and 41.1 in the tapentadol IR and oxycodone IR groups, respectively (least-squares mean difference [95% confidence interval], 9.0 [-18.9, 36.9]; p = 0.527). Secondary analyses of pain intensity, pain relief, and subject satisfaction were similar between groups. Subjects and clinicians reported significantly better global impression of change for tapentadol IR. Adverse events were consistent with established safety profiles for IR opioids.Conclusions: Tapentadol IR and oxycodone IR had similar efficacy for pain after arthroscopic shoulder surgery, but subjects and clinicians reported greater overall improvement with tapentadol IR.

Continuous Interscalene Analgesia with Ropivacaine 2 mg/ml after Major Shoulder Surgery

2003 ◽  
Vol 98 (1) ◽  
pp. 143-150 ◽  
Author(s):  
Georgios Ekatodramis ◽  
Alain Borgeat ◽  
Gunilla Huledal ◽  
Lennart Jeppsson ◽  
Lars Westman ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Visual Analog Scale ◽  
Plasma Concentrations ◽  
Shoulder Surgery ◽  
Interscalene Block ◽  
Postoperative Pain Relief ◽  
Analog Scale ◽  
Threshold Levels ◽  
Continuous Interscalene

Background In this open, randomized study, the pharmacokinetics, clinical efficacy, and safety of a 48-h continuous interscalene infusion of 2 mg/ml ropivacaine for postoperative pain relief were investigated in patients undergoing open major shoulder surgery. Methods An initial interscalene block with 30 ml ropivacaine, 7.5 mg/ml (225 mg), was performed. After completion of interscalene block, all patients (n = 24) received general anesthesia, and 6 h after interscalene block, a 48-h continuous interscalene infusion of 12 or 18 mg/h using 2 mg/ml ropivacaine was started. Total and unbound plasma concentrations of ropivacaine and 2.6-pipecoloxylidide (PPX; a major active metabolite) were determined during and up to 6 h after the interscalene infusion. Postoperative pain at rest was assessed by a visual analog scale. Supplementary analgesics and adverse events were recorded. Results Plasma concentrations of total and unbound ropivacaine were proportional to the total dose. At the end of the interscalene infusion of 9 ml/h, the mean +/- SD plasma concentrations of total and unbound ropivacaine were 1.40 +/- 0.54 and 0.03 +/- 0.01 mg/l, respectively, and of total and unbound PPX were 0.70 +/- 0.38 and 0.30 +/- 0.20 mg/l, respectively. Plasma concentrations of unbound ropivacaine and unbound PPX, added together, remained well below threshold levels for systemic central nervous system toxicity. There were no significant differences between the groups for postoperative pain (median maximum of about 20 mm on the visual analog scale in both groups), analgesic consumption, or quality of pain relief assessed by the patient. No signs or symptoms of systemic local anesthetic toxicity were observed. Conclusion A 48-h continuous interscalene infusion of 6 or 9 ml/h ropivacaine, 2 mg/ml, started 6 h after an initial interscalene block of 30 ml ropivacaine, 7.5 mg/ml, provided satisfactory postoperative pain relief after major shoulder surgery and was well tolerated. Unbound plasma concentrations of ropivacaine and PPX remained well below threshold levels for systemic central nervous toxicity.

Sign in / Sign up

Export Citation Format

Share Document